Biopharmaceutical Industry

Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.

Wainua Phase 3 Setback Clouds TTR Silencers, Strengthening The Case For ATTR-CM Stabilizers

Jonathan BlakeAug 29, 2026

Teva Sets $57.5 Million Floor For BioXcel Assets, Tying More Value To BXCL501 FDA Timing

Emily CarterAug 28, 2026

AstraZeneca And Amgen Post Tezspire EoE Phase 3 Win, Opening A Dosing-Based Challenge To Dupixent

Michael TorresAug 28, 2026

Featured

BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer

BioNTech and Genentech terminated a phase 2 study of autogene cevumeran in surgically removed stage 2 or 3 colorectal cancer after an independent Data Safety Monitoring Board identified a numerical imbalance in overall survival. The outcome weakens the case for personalized mRNA cancer vaccines as monotherapy in immunotherapy-insensitive tumors while leaving combination studies intact.

Dr. Priya NandakumarAug 29, 2026

Read featured

ALL INTELLIGENCE

Biopharmaceutical Industry

BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer

Dr. Priya NandakumarAug 29, 20262 min

Biopharmaceutical Industry

Wainua Phase 3 Setback Clouds TTR Silencers, Strengthening The Case For ATTR-CM Stabilizers

New figures from AstraZeneca and Ionis’ failed Phase 3 ATTR-CM study make the miss look worse than many expected. The readout shifts attention back toward oral stabilizers and raises new questions about combination use of TTR silencers.

Jonathan BlakeAug 29, 20262 min

Biopharmaceutical Industry

Teva Sets $57.5 Million Floor For BioXcel Assets, Tying More Value To BXCL501 FDA Timing

BioXcel Therapeutics filed for Chapter 11 and named Teva Pharmaceuticals as stalking horse bidder for substantially all of its assets. The proposed deal sets a baseline value around a neuroscience portfolio centered on BXCL501, with milestone economics linked to the timing of a pending FDA decision.

Emily CarterAug 28, 20262 min

Biopharmaceutical Industry

AstraZeneca And Amgen Post Tezspire EoE Phase 3 Win, Opening A Dosing-Based Challenge To Dupixent

AstraZeneca and Amgen said Tezspire met Phase 3 goals in eosinophilic esophagitis, a market where Dupixent is the only approved biologic. The result extends Tezspire’s immunology expansion, but the competitive case still depends on data the companies have not yet disclosed.

Michael TorresAug 28, 20262 min

Biopharmaceutical Industry

Roivant Wins Lisraya Approval In Dermatomyositis, Adding A Once-Daily Pill For A Rare Autoimmune Disease

The Food and Drug Administration approved Roivant and Priovant's brepocitinib for dermatomyositis. The decision gives patients a new oral option in a disease where high-dose steroids and other immune-suppressing drugs are the current standard of care.

Michael TorresAug 28, 20261 min

Biopharmaceutical Industry

Osivax Licenses GC FLU Rights Outside Japan And Korea, Advancing A Single-Shot Flu Combination Plan

Osivax has licensed GC Biopharma’s influenza vaccine outside Japan and Korea to build a combination candidate with OVX836. The deal turns earlier co-administration data into a more commercially practical push for a single flu shot.

Dr. Priya NandakumarAug 27, 20262 min

Biopharmaceutical Industry

Akeso Reports Phase 3 Ivonescimab Survival Win In Biliary Tract Cancer, Extending Its Case Beyond Lung Cancer

Akeso said ivonescimab plus chemotherapy beat AstraZeneca’s Imfinzi plus chemotherapy on overall survival in a China phase 3 trial in first-line advanced biliary tract cancer. The result gives the company its first late-stage success for the PD-1xVEGF bispecific outside lung cancer while investors remain focused on Summit Therapeutics’ upcoming Harmoni-3 readout in NSCLC.

Daniel ChoAug 27, 20264 min

Biopharmaceutical Industry

Revolution Medicines Wins FDA Approval For Rasonque In Metastatic Pancreatic Adenocarcinoma, Months Ahead Of Deadline

The FDA approved Revolution Medicines’ daraxonrasib, now branded Rasonque, for adults with metastatic pancreatic adenocarcinoma after practice-changing phase 3 data. The early decision gives the company an entry point in one of oncology’s hardest-to-treat markets while it pushes the drug into earlier settings.

Sophia ReynoldsAug 26, 20263 min

Biopharmaceutical Industry

Jazz Wins First-Line Ziihera Approval In Gastroesophageal Adenocarcinoma, Expanding Its Largest Franchise Opportunity

Jazz Pharmaceuticals has added a first-line gastroesophageal adenocarcinoma indication to Ziihera, extending the bispecific antibody beyond its earlier biliary tract cancer approval. The decision matters because Truist sees GEA as about 90% of its peak sales model for the product.

Emily CarterAug 26, 20262 min

Biopharmaceutical Industry

Johnson & Johnson Wins Imaavy Approval In Warm Autoimmune Hemolytic Anemia, Adding A First FDA-Approved Option

Johnson & Johnson’s Imaavy is now approved for patients age 12 and older with warm autoimmune hemolytic anemia, giving the disease its first FDA-approved therapy. The decision expands a product J&J already markets in generalized myasthenia gravis and broadens the commercial case for FcRn blockade in immunology.

Jonathan BlakeAug 25, 20262 min

Biopharmaceutical Industry

Lilly Launches Foundayo In The U.K., Extending The Oral Obesity Race Beyond The U.S.

Eli Lilly has launched Foundayo in the U.K. through private prescriptions after MHRA approval earlier this month. The move brings Lilly into more direct competition with Novo Nordisk in oral obesity treatment outside the U.S., where pricing and manufacturing economics may matter more.

Dr. Priya NandakumarAug 25, 20261 min